NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Orbimed Advisors Llc sold 1,781 shares of NeuroPace stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $14.06, for a total transaction of $25,040.86. Following the completion of the sale, the insider now owns 3,435,541 shares of the company’s stock, valued at $48,303,706.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Monday, April 22nd, Orbimed Advisors Llc sold 24,609 shares of NeuroPace stock. The stock was sold at an average price of $14.05, for a total transaction of $345,756.45.
- On Thursday, April 18th, Orbimed Advisors Llc sold 2,623 shares of NeuroPace stock. The stock was sold at an average price of $14.06, for a total transaction of $36,879.38.
- On Tuesday, April 16th, Orbimed Advisors Llc sold 14,069 shares of NeuroPace stock. The stock was sold at an average price of $14.01, for a total transaction of $197,106.69.
- On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The stock was sold at an average price of $14.49, for a total transaction of $6,692,916.51.
NeuroPace Price Performance
NeuroPace stock traded up $0.40 during trading on Friday, reaching $13.39. The company had a trading volume of 69,085 shares, compared to its average volume of 105,007. The firm’s 50-day simple moving average is $14.31 and its 200 day simple moving average is $11.55. NeuroPace, Inc. has a 1-year low of $3.80 and a 1-year high of $18.15. The firm has a market capitalization of $384.56 million, a PE ratio of -10.46 and a beta of 2.08. The company has a debt-to-equity ratio of 2.76, a quick ratio of 5.02 and a current ratio of 5.71.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the stock. SVB Leerink began coverage on shares of NeuroPace in a research report on Tuesday, January 30th. They set an “outperform” rating and a $22.00 price target for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of NeuroPace in a report on Tuesday, January 30th. Cantor Fitzgerald lifted their target price on shares of NeuroPace from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Morgan Stanley lifted their target price on shares of NeuroPace from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Wednesday, March 6th. Finally, Wells Fargo & Company raised shares of NeuroPace from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $16.00 to $20.00 in a report on Thursday, March 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, NeuroPace has a consensus rating of “Moderate Buy” and an average target price of $15.67.
View Our Latest Stock Report on NeuroPace
Institutional Investors Weigh In On NeuroPace
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. acquired a new position in shares of NeuroPace during the 3rd quarter valued at about $29,000. Barclays PLC raised its holdings in NeuroPace by 9,085.6% in the 3rd quarter. Barclays PLC now owns 10,839 shares of the company’s stock valued at $105,000 after buying an additional 10,721 shares during the period. EAM Investors LLC purchased a new stake in NeuroPace in the 3rd quarter valued at about $1,378,000. Finally, Kent Lake Capital LLC raised its holdings in NeuroPace by 285.0% in the 3rd quarter. Kent Lake Capital LLC now owns 574,417 shares of the company’s stock valued at $5,589,000 after buying an additional 425,212 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Articles
- Five stocks we like better than NeuroPace
- What is the Euro STOXX 50 Index?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Technology Stocks Explained: Here’s What to Know About Tech
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Canada Bond Market Holiday: How to Invest and Trade
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.